BeiGene, Ltd. (NASDAQ:BGNE) Q1 2025 Earnings Call Transcript
Dan Maller: [Abrupt Start]…our Investor Relations website, along with our earnings release.
Beigene Ltd. (BGNE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 25,141 | $6,842,626 | +131% | 3.02% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 2,900 | $789,293 | +45% | 0.01% |
| 3. | RWC Asset Management Tord Stallvik (Ceo) | 839 | $228,351 | 0.01% | |
| 4. | Bayforest Capital Theodoros Tsagaris | 1,129 | $215,286 | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.06 | 165,529 | Large Shareholder | 18,943,802 | 2021-09-10 | Filing | |
| $108.00 | 5,231,900 | Large Shareholder, Director | 5,250,491 | 2018-08-02 | Filing | |
| $108.00 | 582,200 | Large Shareholder, Director | 600,791 | 2018-08-02 | Filing | |
| $101.00 | 1,645,148 | Large Shareholder, Director | 5,121,404 | 2018-01-18 | Filing | |
| $101.00 | 335,050 | Large Shareholder, Director | 708,025 | 2018-01-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $249.45 | 365 | Director, Other | 0 | 2025-04-14 | Filing | |
| $248.90 | 535 | Director, Other | 365 | 2025-04-14 | Filing | |
| $247.46 | 1,475 | Director, Other | 900 | 2025-04-14 | Filing | |
| $246.40 | 1,869 | Director, Other | 2,375 | 2025-04-14 | Filing | |
| $245.56 | 2,056 | Director, Other | 4,244 | 2025-04-14 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,055,504 | $1,375,956,527 | 1.14% | |
| 2. | 3,630,710 | $988,170,340 | 0.86% | |
| 3. | 582,290 | $158,481,870 | 0% | |
| 4. | 116,104 | $31,600,026 | 0.03% | |
| 5. | 98,138 | $26,710,124 | 0% |
News See All
BeiGene, Ltd. (NASDAQ:BGNE) Q4 2024 Earnings Call Transcript
Operator: Good day, everyone. Welcome to BeiGene's Q4 and Full Year 2024 Earnings Call Webcast. All lines have been placed on mute to prevent any background noise.
10 High Growth Healthcare Stocks to Invest in Now
During lean economic times, investing in healthcare stocks is generally regarded as defensive.
12 High Growth Large Cap Stocks to Buy Now
BlackRock highlighted that its portfolio managers are broadly optimistic about US equities.
Here's Why BeiGene, Ltd. (BGNE) Rallied in Q3
Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the “Baird Chautauqua International and Global Growth Fund” third quarter 2024 investor letter...
5 Most Promising Stocks to Buy Before They Take Off
In this article, we discuss the 5 most promising stocks to buy before they take off.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
10 Blue-Chip Stocks At 52-Week Lows
The end of January has provided the media and investors with crucial information from the Federal Reserve just in time to set expectations of what to expect from the market and the economy moving forward...
12 High Growth International Stocks to Buy
In this article, we discuss the 12 high growth international stocks to buy.
Billionaire Hedge Funds
